David T. Rubin to Cost-Benefit Analysis
This is a "connection" page, showing publications David T. Rubin has written about Cost-Benefit Analysis.
Connection Strength
0.218
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
Score: 0.161
-
Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. J Infect. 2020 11; 81(5):758-765.
Score: 0.039
-
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
Score: 0.017